Huons Biopharma, a Huons Group company specializing in botulinum toxin, said April 14 it has appointed Lee Jeong-hee, an executive director, as its new CEO.
Lee, born in 1976, earned an MBA from Aalto University in Finland. He has more than 23 years of experience in the dermatology and medical aesthetics market, working in marketing, sales and strategic planning at Ipsen Korea, Hanwha Pharma, Hugel, Daewoong Pharmaceutical, Jetema and Chong Kun Dang Bio, among others.
The company said Lee was credited with helping lay the groundwork for global expansion while leading overseas business development at Hugel and Daewoong Pharmaceutical.
Huons Biopharma in January received product approval from China’s National Medical Products Administration for its botulinum toxin Hutox (sold domestically as Liztox) in a 100-unit dose, and began its first shipments last month.
“Huons Biopharma is at an important turning point as it has secured approval in China for its botulinum toxin product and is moving into full-scale exports,” Lee said. “We will accelerate exports to China in the second half and expand R&D for next-generation products to sustain growth.”
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.